News Releases

NimbuDerm™ Receives Wound Healing Society's Prestigious Blue Ribbon Award

Download PDF

Gainesville, Florida – May 14, 2008 – Quick-Med Technologies, Inc. is pleased to announce that a team of scientists from Quick-Med received the Blue Ribbon Award at the Symposium on Advanced Wound Care and Wound Healing Society’s 21st Annual Meeting for the outstanding abstract entitled: “Persistent Skin Sanitizer (NimbuDerm™) with Sustained Microbicidal Properties.” The abstract was sponsored by Quick-Med Technologies and the University of Florida at Gainesville.

The Wound Healing Society offers the Blue Ribbon Industrial Research & Development Award to recognize the best product-oriented research performed by research and development scientists within the corporate world. This year, a total of 11 blue ribbons were awarded including 2 to teams from Quick-Med Technologies. Other participants at the SAWC/WHS event were prominent companies such as Johnson & Johnson Wound Management, 3M Healthcare, Kinetic Concepts, Inc., and Healthpoint, Ltd., as well as leading educational institutions such as the Harvard Medical School, Stanford University, and the University of Pennsylvania School of Medicine.

“We are honored to receive this important recognition from such a prestigious organization as the Wound Healing Society”, said J. Ladd Greeno, CEO of Quick-Med Technologies. “NimbuDerm technology represents an important breakthrough that has the potential to dramatically improve hand hygiene by combining the power of an instant sanitizer with long-lasting personal protection.”

This project team is lead by David Moore1 and includes William Toreki1, Roy Carr1, Gregory Schultz1,2, Christopher Batich1,2, Albina Mikhaylova1, , Jillian Vella1,  and Gerald Olderman1. (1Quick-Med Technologies; Inc.; 2University of Florida)

Human use tests show that NimbuDerm is both instant and provides a high level of continuing antimicrobial protection for 6 hours after application without wearing off or losing its effectiveness. Poor hand hygiene is considered to be a major contributor to the spread of infectious diseases and the increase of potentially deadly methicillin-resistant Staphylococcus aureus, or MRSA infections.

NimbuDerm, an extension of Quick-Med’s NIMBUS® technology, opens up new application vistas as a result of its liquid form, unique properties, and formulation flexibility.

The poster in its entirety can be accessed by clicking here.

About the Wound Healing Society

The Wound Healing Society is a non-profit organization composed of clinical and basic scientists. The Society provides a forum for interaction among scientists, physicians, licensed practitioners, industrial representatives and government agencies. Founded in 1990, the Society is recognized among professionals and government agencies as the leading scientific organization focused in this area of wound healing. The Society publishes the leading journal in this area, Wound Repair and Regeneration.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see:    


Natasha A. Sorobey, Investor & Media Relations

Tel. (888) 835.2211 Ext 107


© 2008 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at